NO20013220L - Trombin inhibitorer - Google Patents

Trombin inhibitorer

Info

Publication number
NO20013220L
NO20013220L NO20013220A NO20013220A NO20013220L NO 20013220 L NO20013220 L NO 20013220L NO 20013220 A NO20013220 A NO 20013220A NO 20013220 A NO20013220 A NO 20013220A NO 20013220 L NO20013220 L NO 20013220L
Authority
NO
Norway
Prior art keywords
thrombin inhibitors
formula
anticoagulants
class
compounds
Prior art date
Application number
NO20013220A
Other languages
English (en)
Other versions
NO321739B1 (no
NO20013220D0 (no
Inventor
Koo Lee
Won Hyuk Jung
Cheol Won Park
Sang Koo Lee
Sun Hwa Lee
Hee Dong Park
Original Assignee
Lg Ci Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lg Ci Ltd filed Critical Lg Ci Ltd
Publication of NO20013220D0 publication Critical patent/NO20013220D0/no
Publication of NO20013220L publication Critical patent/NO20013220L/no
Publication of NO321739B1 publication Critical patent/NO321739B1/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D205/00—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom
    • C07D205/02—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings
    • C07D205/06—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
    • C07D205/08—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with one oxygen atom directly attached in position 2, e.g. beta-lactams
    • C07D205/085—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with one oxygen atom directly attached in position 2, e.g. beta-lactams with a nitrogen atom directly attached in position 3
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/02—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link
    • C07K5/022—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link containing the structure -X-C(=O)-(C)n-N-C-C(=O)-Y-; X and Y being heteroatoms; n being 1 or 2
    • C07K5/0222—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link containing the structure -X-C(=O)-(C)n-N-C-C(=O)-Y-; X and Y being heteroatoms; n being 1 or 2 with the first amino acid being heterocyclic, e.g. Pro, Trp
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06008—Dipeptides with the first amino acid being neutral
    • C07K5/06078—Dipeptides with the first amino acid being neutral and aromatic or cycloaliphatic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biochemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Saccharide Compounds (AREA)
NO20013220A 1998-12-29 2001-06-27 Nye forbindelser som er trombin-inhibitorer NO321739B1 (no)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
KR19980060266 1998-12-29
KR1019990033490A KR20000047461A (ko) 1998-12-29 1999-08-14 트롬빈 억제제
PCT/KR1999/000830 WO2000039124A1 (en) 1998-12-29 1999-12-29 Thrombin inhibitors

Publications (3)

Publication Number Publication Date
NO20013220D0 NO20013220D0 (no) 2001-06-27
NO20013220L true NO20013220L (no) 2001-08-27
NO321739B1 NO321739B1 (no) 2006-06-26

Family

ID=26634497

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20013220A NO321739B1 (no) 1998-12-29 2001-06-27 Nye forbindelser som er trombin-inhibitorer

Country Status (22)

Country Link
US (2) US6492402B1 (no)
EP (1) EP1140918B1 (no)
JP (1) JP3847092B2 (no)
KR (2) KR20000047461A (no)
CN (1) CN1149210C (no)
AT (1) ATE273305T1 (no)
AU (1) AU765417B2 (no)
BR (1) BR9916678A (no)
CA (1) CA2355281A1 (no)
CZ (1) CZ20012429A3 (no)
DE (1) DE69919397T2 (no)
DK (1) DK1140918T3 (no)
ES (1) ES2226482T3 (no)
HK (1) HK1044936A1 (no)
HU (1) HUP0104500A3 (no)
IL (1) IL143545A (no)
NO (1) NO321739B1 (no)
NZ (1) NZ513174A (no)
RU (1) RU2221808C2 (no)
TR (1) TR200101899T2 (no)
WO (1) WO2000039124A1 (no)
ZA (1) ZA200104780B (no)

Families Citing this family (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7144902B1 (en) * 1999-04-09 2006-12-05 Abbott Gmbh & Co. Kg Prodrugs of thrombin inhibitors
DE19934066A1 (de) * 1999-07-23 2001-01-25 Basf Ag Verfahren zur Herstellung von 4-Cyano-2-aminomethylthiazol
DE19933861A1 (de) * 1999-07-23 2001-01-25 Basf Ag Verfahren zur Herstellung von 2-Aminomethyl-4-cyano-thiazol
DE10049937A1 (de) * 2000-10-06 2002-04-11 Knoll Ag Niedermolekulare Inhibitoren von Serinproteasen mit Polyhydroxyalkyl- und Polyhydroxycycloalkylresten
KR100447421B1 (ko) * 2001-04-04 2004-09-07 주식회사 엘지생명과학 5-(아미노메틸)-2-티오펜카보니트릴 염산염의 연속반응에의한 새로운 제조방법
EP1497283A4 (en) * 2002-03-22 2006-01-11 Lg Life Sciences Ltd (2S) -N-5-AMINO (IMINO) METHYL-2-THIENYL METHYL-1- (2R) -2- (CARBOXYMETHYL) AMINO) 3,3-DIPHENYLPROPANOYL -2-PYRROLIDINE CARBOXAMIDE MALEIC ACID SALT AND PROCESS OF PREPARATION CORRESPONDING
JP2005526800A (ja) * 2002-03-22 2005-09-08 エルジー・ライフ・サイエンシーズ・リミテッド (2S)−N−5−[アミノ(イミノ)メチル]−2−チエニルメチル−1−(2R)−2−[(カルボキシルメチル)アミノ]−3,3−ジフェニルプロパノイル−2−ピロリジンカルボキサミド・nH2Oの新しい結晶形
WO2004002985A1 (en) * 2002-06-27 2004-01-08 Lg Life Sciences Ltd. Peptidic thrombin inhibitor compound
US7097967B2 (en) 2002-10-24 2006-08-29 Lg Life Sciences Ltd. Method of predicting drug-food interaction
US7399870B2 (en) * 2004-03-30 2008-07-15 Wyeth Synthesis of pyrrole-2-carbonitriles
GB0507577D0 (en) 2005-04-14 2005-05-18 Novartis Ag Organic compounds
US7678917B2 (en) * 2005-09-01 2010-03-16 Hoffman-La Roche Inc. Factor Xa inhibitors
NZ567140A (en) 2005-10-07 2011-09-30 Exelixis Inc Azetidines as MEK inhibitors for the treatment of proliferative diseases
EP2027143A2 (en) 2006-05-23 2009-02-25 Irm Llc Compounds and compositions as channel activating protease inhibitors
JP2008115178A (ja) 2006-11-03 2008-05-22 Ajinomoto Co Inc ジフェニルアラニン−Ni(II)錯体の製造方法
CA2677487A1 (en) 2007-02-09 2008-08-14 Irm Llc Compounds and compositions as channel activating protease inhibitors
WO2008135525A2 (en) * 2007-05-02 2008-11-13 Boehringer Ingelheim International Gmbh Substituted azetidines, manufacturing and use thereof as medicaments
SG10201502484SA (en) 2010-03-30 2015-05-28 Verseon Corp Multisubstituted aromatic compounds as inhibitors of thrombin
US9273028B2 (en) 2010-10-29 2016-03-01 Biogen Ma Inc. Heterocyclic tyrosine kinase inhibitors
SI2909188T1 (en) 2012-10-12 2018-07-31 Exelixis, Inc. A novel process for the manufacture of compounds for use in the treatment of cancer
WO2014149139A2 (en) 2013-03-15 2014-09-25 Verseon, Inc. Halogenopyrazoles as inhibitors of thrombin
DK2968297T3 (en) 2013-03-15 2019-01-07 Verseon Inc MULTI-SUBSTITUTED AROMATIC COMPOUNDS AS SERINE PROTEASE INHIBITORS
JP2017528486A (ja) 2014-09-17 2017-09-28 ヴァーセオン コーポレイション セリンプロテアーゼ阻害剤としてのピラゾリル置換ピリドン化合物
ES2931460T3 (es) 2015-02-27 2022-12-29 Verseon Int Corporation Compuestos de pirazol sustituido como inhibidores de serina proteasa
WO2017035409A1 (en) 2015-08-26 2017-03-02 Achillion Pharmaceuticals, Inc. Aryl, heteroaryl, and heterocyclic compounds for treatment of immune and inflammatory disorders
WO2017035405A1 (en) 2015-08-26 2017-03-02 Achillion Pharmaceuticals, Inc. Amino compounds for treatment of immune and inflammatory disorders
WO2017035401A1 (en) 2015-08-26 2017-03-02 Achillion Pharmaceuticals, Inc. Amide compounds for treatment of immune and inflammatory disorders
AR106018A1 (es) 2015-08-26 2017-12-06 Achillion Pharmaceuticals Inc Compuestos de arilo, heteroarilo y heterocíclicos para el tratamiento de trastornos médicos
WO2018160891A1 (en) 2017-03-01 2018-09-07 Achillion Pharmaceutical, Inc. Pharmaceutical compounds for treatment of medical disorders
CA3053818A1 (en) 2017-03-01 2018-09-07 Achillion Pharmaceuticals, Inc. Aryl, heteroaryl, and heterocyclic pharmaceutical compounds for treatment of medical disorders
WO2019231935A1 (en) 2018-05-29 2019-12-05 Omeros Corporation Masp-2 inhibitors and methods of use
WO2020051538A1 (en) 2018-09-06 2020-03-12 Achillion Pharmaceuticals, Inc. Morphic forms of complement factor d inhibitors
WO2020069024A1 (en) 2018-09-25 2020-04-02 Achillion Pharmaceuticals, Inc. Morphic forms of complement factor d inhibitors
CN113195472A (zh) 2018-12-17 2021-07-30 艾其林医药公司 用于治疗补体介导的病症的靶向给药
MX2021011507A (es) 2019-03-22 2021-12-15 Achillion Pharmaceuticals Inc Compuestos farmaceuticos para el tratamiento de trastornos mediados por complemento.
BR112022010895A2 (pt) 2019-12-04 2022-09-06 Omeros Corp Composto, composição farmacêutica, e, método para tratar uma doença ou distúrbio associado à serina protease-2 associada à lectina de ligação ao manan
JP7699389B2 (ja) 2019-12-04 2025-06-27 オメロス コーポレーション Masp-2阻害剤および使用方法
AU2020395306B2 (en) 2019-12-04 2025-04-24 Omeros Corporation MASP-2 inhibitors and methods of use
JP7764808B2 (ja) * 2021-08-11 2025-11-06 Jsr株式会社 液晶配向剤、液晶配向膜及びその製造方法、液晶素子並びに重合体
WO2023183405A2 (en) * 2022-03-22 2023-09-28 Alexion Pharmaceuticals, Inc. Pharmaceutical compounds for the treatment of complement mediated disorders

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2008116C (en) * 1989-02-23 2001-11-20 Thomas Weller Glycine derivatives
SE9301916D0 (sv) * 1993-06-03 1993-06-03 Ab Astra New peptides derivatives
US5705487A (en) * 1994-03-04 1998-01-06 Eli Lilly And Company Antithrombotic agents
ZA951617B (en) * 1994-03-04 1997-02-27 Lilly Co Eli Antithrombotic agents.
US5726159A (en) * 1994-03-04 1998-03-10 Eli Lilly And Company Antithrombotic agents
US5707966A (en) * 1994-03-04 1998-01-13 Eli Lilly And Company Antithrombotic agents
CA2210989A1 (en) 1995-02-10 1996-08-15 Basf Aktiengesellschaft Thrombin inhibitors
US5914319A (en) 1995-02-27 1999-06-22 Eli Lilly And Company Antithrombotic agents
US5710130A (en) * 1995-02-27 1998-01-20 Eli Lilly And Company Antithrombotic agents
SA96170106A (ar) * 1995-07-06 2005-12-03 أسترا أكتيبولاج مشتقات حامض أميني جديدة
IL123986A (en) * 1997-04-24 2011-10-31 Organon Nv Medicinal compounds
WO1999037668A1 (de) * 1998-01-26 1999-07-29 Basf Aktiengesellschaft Thrombininhibitoren
AU2424499A (en) * 1998-01-26 1999-08-09 Basf Aktiengesellschaft Heterocyclic amidines as callicrein protease inhibitors

Also Published As

Publication number Publication date
JP3847092B2 (ja) 2006-11-15
ZA200104780B (en) 2003-06-12
KR20000047461A (ko) 2000-07-25
DE69919397T2 (de) 2005-07-28
CN1332737A (zh) 2002-01-23
KR20010086468A (ko) 2001-09-12
RU2221808C2 (ru) 2004-01-20
HUP0104500A2 (hu) 2002-04-29
NZ513174A (en) 2003-10-31
EP1140918B1 (en) 2004-08-11
DE69919397D1 (de) 2004-09-16
KR100462974B1 (ko) 2004-12-23
ES2226482T3 (es) 2005-03-16
DK1140918T3 (da) 2004-12-20
ATE273305T1 (de) 2004-08-15
NO321739B1 (no) 2006-06-26
WO2000039124A1 (en) 2000-07-06
AU765417B2 (en) 2003-09-18
IL143545A0 (en) 2002-04-21
JP2002533460A (ja) 2002-10-08
AU1895100A (en) 2000-07-31
CZ20012429A3 (cs) 2001-10-17
BR9916678A (pt) 2001-10-16
CA2355281A1 (en) 2000-07-06
EP1140918A1 (en) 2001-10-10
IL143545A (en) 2005-08-31
US6864249B2 (en) 2005-03-08
HUP0104500A3 (en) 2002-06-28
NO20013220D0 (no) 2001-06-27
CN1149210C (zh) 2004-05-12
US20030134801A1 (en) 2003-07-17
TR200101899T2 (tr) 2001-12-21
HK1044936A1 (zh) 2002-11-08
US6492402B1 (en) 2002-12-10

Similar Documents

Publication Publication Date Title
DK1140918T3 (da) Thrombininhibitorer
ATE297203T1 (de) Antithrombotische mitteln
CY1107634T1 (el) Φαρμακευτικη συνθεση
ATE306261T1 (de) Antithrombosemittel
EA199900937A1 (ru) Фармацевтические композиции, содержащие вориконазол
BR0108893B1 (pt) composiÇço farmacÊutica contendo derivados de azetidina, composto derivado de azetidina, e, processo para a preparaÇço de compostos.
DE602004008098D1 (de) Substituierte 2h-ä1,2,4ütriazoloä4,3-aüpyrazine als gsk-3-inhibitoren
DE69919212D1 (de) Aromatische amiden
DK0705254T3 (da) Phenylheterocykliske forbindelser som cyclooxygenase-2-inhibitorer
SE9203825D0 (sv) Dual inhibitors of no synthase and cyclooxygenase, process for their preparation and therapeutical compositions containing them
EE200200045A (et) Asendatud oksoasaheterotsüklüülühendid, farmatseutiline kompositsioon ja vaheühendid
NO20003018L (no) Triazinangiogenese-inhibitorer
NO991494D0 (no) <beta>-sulfonylhydroksaminsyrer som matriksmetalloproteinaseinhibitorer
BR9907300A (pt) Inibidores do fator xa oxoaza-heterociclila substituìdos
DE69931393D1 (de) Antithrombotische amide
WO2003082205A3 (en) Compounds and methods
EA200500312A1 (ru) Новые спироконденсированные хиназолиноны и их применение в качестве ингибиторов фосфодиэстераз
EA200000804A1 (ru) Мета-азациклические соединения аминобензойной кислоты и их производные, являющиеся ингибиторами интегрина
DK0715623T3 (da) Blodpladeaggregationsinhibitorer
UY26780A1 (es) Cicloalquil avb3 antagonistas
BR9809062A (pt) Inibidores da metaloproteinase, composições farmacêuticas comtendo os mesmos e seus usos farmacêuticos
CO5261493A1 (es) Procedimiento y compuestos para la inhibicion de la mrp1
DE60330758D1 (de) Bestimmte pharmazeutisch wertvolle substituierte aminoalkyl-heterocyclen
ATE308540T1 (de) Antithrombosemittel
DK0804418T3 (da) Platelataggregationshæmmere